Efficacy and Safety of Iguratimod Combined with Methotrexate Vs. Methotrexate Alone in Rheumatoid Arthritis : A systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2020 Dec 21

PMID 33346891

Citations 1

Authors

L-J Chen

Y-J Zhou

Z-H Wen

F Tian

J-Y Li

Affiliations

Soon will be listed here.

Abstract

The current systematic review and meta-analysis aims to evaluate the efficacy and safety of iguratimod (IGU) combined with methotrexate (MTX) versus MTX alone in rheumatoid arthritis (RA). Two independent investigators searched for original randomized controlled trials (RCTs) related to the combination of IGU and MTX in RA published before November 1, 2019, in PubMed, Cochrane Library, Embase, the China National Knowledge Infrastructure (CNKI), the Chinese Biomedical Literature Database (CBM), and WanFang Data. Additionally, we searched clinical trial registry websites. We assessed the methodological quality of the included trials using the Cochrane Collaboration tool and the seven-point Jadad scale. Statistical analyses were performed using Review Manager (RevMan) 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). Meta-regression and publication bias analyses were performed using Stata version 14 software (StataCorp., College Station, TX, USA). A total of 7 RCTs consisting of 665 participants, with 368 participants in the active arm and 297 in the placebo arm, were included in the meta-analysis. The American College of Rheumatology (ACR) value was better in the IGU + MTX group than in the MTX alone group, with a pooled relative risk (RR) for ACR20 (American College of Rheumatology 20% improvement criteria), ACR50, and ACR70 of 1.40 (95% CI, 1.13-1.74), 2.09 (95% CI, 1.67-2.61), and 2.24 (95% CI, 1.53-3.28), respectively. The results of the meta-analysis demonstrated that there was no statistical significance in adverse events (1.06 (95% CI, 0.92-1.23)). The combined treatment is an effective, safe, and economical treatment option for patients who do not respond well to methotrexate alone or for patients who cannot afford expensive biologics that have no confirmed efficacy.

Citing Articles

The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial.

Zeng L, Yu G, Yang K, Hao W, Chen H Front Pharmacol. 2022; 12:780154.

PMID: 35115930 PMC: 8804504. DOI: 10.3389/fphar.2021.780154.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F . A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol. 2013; 191(10):4969-78. DOI: 10.4049/jimmunol.1300832. View

Duan X, Zhang X, Mao S, Shang J, Shi X . Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol. 2015; 34(9):1513-9. DOI: 10.1007/s10067-015-2999-6. View

Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A . Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med. 1999; 133(6):566-74. DOI: 10.1016/s0022-2143(99)90186-5. View

Du F, Lu L, Fu Q, Dai M, Teng J, Fan W . T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther. 2008; 10(6):R136. PMC: 2656239. DOI: 10.1186/ar2554. View

Mucke H . Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc). 2012; 48(9):577-86. DOI: 10.1358/dot.2012.48.9.1855758. View

Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T . Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2012; 23(3):430-9. DOI: 10.1007/s10165-012-0724-8. View

Du F, Lu L, Teng J, Shen N, Ye P, Bao C . T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. Int Immunopharmacol. 2012; 13(1):54-60. DOI: 10.1016/j.intimp.2012.03.003. View

Singh J, Saag K, Bridges Jr S, Akl E, Bannuru R, Sullivan M . 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2015; 68(1):1-25. DOI: 10.1002/acr.22783. View

10.

Song J, Liu H, Zhu Q, Miao Y, Wang F, Yang F . T-614 Promotes Osteoblastic Cell Differentiation by Increasing Dlx5 Expression and Regulating the Activation of p38 and NF-B. Biomed Res Int. 2018; 2018:4901591. PMC: 5836304. DOI: 10.1155/2018/4901591. View

11.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View

12.

Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T . Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013; 24(3):410-8. DOI: 10.3109/14397595.2013.843756. View

13.

Xia Z, Lyu J, Hou N, Song L, Li X, Liu H . Iguratimod in combination with methotrexate in active rheumatoid arthritis : Therapeutic effects. Z Rheumatol. 2015; 75(8):828-833. DOI: 10.1007/s00393-015-1641-y. View

14.

Gan K, Yang L, Xu L, Feng X, Zhang Q, Wang F . Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways. Int Immunopharmacol. 2016; 35:294-300. DOI: 10.1016/j.intimp.2016.03.038. View

15.

Jiang X, Huang X, Yang Z, Wang S, Xie W, Miao L . Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis. Mol Immunol. 2017; 93:9-19. DOI: 10.1016/j.molimm.2017.10.008. View

16.

Ishikawa K, Ishikawa J . Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients. Mod Rheumatol. 2018; 29(3):418-429. DOI: 10.1080/14397595.2018.1481565. View

17.

Aikawa Y, Tanuma N, Shin T, Makino S, Tanaka K, Matsumoto Y . A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol. 1998; 89(1-2):35-42. DOI: 10.1016/s0165-5728(98)00056-3. View

18.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

19.

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

20.

Sun Y, Ye D, Zhang P, Wu Y, Wang B, Peng G . Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner. J Huazhong Univ Sci Technolog Med Sci. 2016; 36(5):691-699. DOI: 10.1007/s11596-016-1646-z. View